Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2023-06-12 00:00:00 ET · period of report 2023-06-08 · accession 0001209191-23-036261 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-06-12 | 2023-06-08+ | KROS | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 20.0K | New | +$640.0K |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Regnante Keith | CFO | S - Sale+OE | $46.61 | -40.0K | 2,699 | -94% | -$1.86M |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Regnante Keith | CFO | M - OptEx | $0.00 | -40.0K | 113.6K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-09 | M | A | 20,000 | $16.00 | 20,000 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-09 | S | D | 2,579 | $47.25 | 0 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.015 to $47.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2023-06-09 | S | D | 1,428 | $46.46 | 2,579 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.015 to $47.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2023-06-09 | S | D | 15,993 | $45.03 | 4,007 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.995 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2023-06-08 | S | D | 2,699 | $48.65 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2023-06-08 | S | D | 17,301 | $47.66 | 2,699 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.12 to $48.095 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2023-06-08 | M | A | 20,000 | $16.00 | 20,000 | D | — | — | |
| 8 | Derivative | Employee Stock Option (right to buy) | 2023-06-09 | M | D | 20,000 | $0.00 | 93,622 | D | $16.00 · — to 2030-04-06 | 20,000 Common Stock | (F7) One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2023-06-08 | M | D | 20,000 | $0.00 | 113,622 | D | $16.00 · — to 2030-04-06 | 20,000 Common Stock | (F7) One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |